Comparison of Clinical Outcomes in Nonintubated Patients with Severe Alcohol Withdrawal Syndrome Treated with Continuous-Infusion Sedatives: Dexmedetomidine versus Benzodiazepines

Crispo, Angela; Daley, Mitchell J.; Pepin, Jodie L.; Harford, Paul H.; Brown, Carlos

doi:10.1002/phar.1448

Cited by 36 publications

(66 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As ɑ‐2 agonists lack the GABAergic activity to prevent and treat DT or seizures, they can only be used as adjunctive therapy to reduce autonomic hyperactivity that cannot be controlled by BZD alone 3, 80, 86. Several studies demonstrated a BZD‐sparing effect with significant reduction in BZD requirement 87, 88, 89…”

Section: Therapymentioning

confidence: 99%

Alcohol withdrawal syndrome: mechanisms, manifestations, and management

et al. 2016

View full text Add to dashboard Cite

The alcohol withdrawal syndrome is a well‐known condition occurring after intentional or unintentional abrupt cessation of heavy/constant drinking in patients suffering from alcohol use disorders (AUDs). AUDs are common in neurological departments with patients admitted for coma, epileptic seizures, dementia, polyneuropathy, and gait disturbances. Nonetheless, diagnosis and treatment are often delayed until dramatic symptoms occur. The purpose of this review is to increase the awareness of the early clinical manifestations of AWS and the appropriate identification and management of this important condition in a neurological setting.

show abstract

Section: Therapymentioning

confidence: 99%

Alcohol withdrawal syndrome: mechanisms, manifestations, and management

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[14][15][16][17][18][19][20][21] Mueller et al 18 conducted a randomized controlled trial involving 24 patients to evaluate dexmedetomidine as adjunctive therapy to lorazepam in patients with severe AWS. Patients were randomized 2:1 to either placebo or dexmedetomidine.…”

Section: Dexmedetomidine Use In Alcohol Withdrawalmentioning

confidence: 99%

Dexmedetomidine for Alcohol Withdrawal Syndrome

Linn

Loeser

2015

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…Aktuell liegen sechs retrospektive Übersichten, eine prospektive Observationsstudie und eine PRCT (Prospective Randomized Controlled Trial) vor [4,6,10,11,13,16,19,20]. …”

Section: Dexmedetomidin Und Alkoholentzugsdelirvorliegende Evidenzunclassified

Dexmedetomidin in der Therapie des akuten Alkoholentzugsdelirs

2016

View full text Add to dashboard Cite

Alcohol withdrawal syndrome has a high clinical prevalence. Severe cases must be treated in an intensive care unit and are associated with a high mortality rate, depending on patient comorbidities. Clinical requirements include sedation, control of vegetative symptoms, treatment of hallucinations and, when necessary, anticonvulsive therapy. Currently, there is no single substance that fulfills these requirements. National and international guidelines recommend a combination of various substances. The central α2-adrenergic receptor agonist clonidine is used as a therapeutic adjuvant. In consideration of its pharmacological characteristics, dexmedetomidine is assumed to be more advantageous compared to clondine. Case studies with dexmedetomidine in alcohol withdrawal syndrome show the safety of its application and a benzodiazepine-sparing effect. Its incorporation in escalating intensive care therapy of severe cases could be appropriate.

show abstract

Comparison of Clinical Outcomes in Nonintubated Patients with Severe Alcohol Withdrawal Syndrome Treated with Continuous-Infusion Sedatives: Dexmedetomidine versus Benzodiazepines

Cited by 36 publications

References 25 publications

Alcohol withdrawal syndrome: mechanisms, manifestations, and management

Alcohol withdrawal syndrome: mechanisms, manifestations, and management

Dexmedetomidine for Alcohol Withdrawal Syndrome

Dexmedetomidin in der Therapie des akuten Alkoholentzugsdelirs

Contact Info

Product

Resources

About